Common questions about Xeplion (FAQ)
Q: How long does a single Xeplion injection last?
A: Following the two initial doses, the medicine is designed to be administered as a maintenance injection monthly. The official dosing schedule allows for a flexible window of about one week (pm 7 days) around your scheduled monthly date to support consistent therapeutic action.
Q: What is the difference between Xeplion and the 3-month paliperidone injection?
A: Xeplion is the brand name for the one-month long-acting injectable (LAI) formulation of paliperidone palmitate. The 3-month product is a separate formulation that is generally indicated for patients who have already been stabilized on the one-month injection.
Q: Will I have withdrawal symptoms if Xeplion treatment is stopped?
A: The regulatory label mentions a need to monitor newborns for potential withdrawal symptoms if the medicine is used during the third trimester of pregnancy. However, official documents do not describe the general risk of specific withdrawal symptoms for adults upon cessation. Concerns about cessation should be addressed with a healthcare professional.
Q: How often do most people receive Xeplion injections?
A: After receiving the two initial loading doses approximately one week apart, most patients transition into the maintenance phase where the medicine is administered as a single dose once every month.
Q: How is the dose of Xeplion determined by the doctor?
A: Official prescribing information states that while the recommended monthly maintenance dose is 75 mg, a patient may need a dose within the range of 25 mg to 150 mg. Official documents indicate that dose selection, within the approved range, is often influenced by factors such as a patient’s tolerability and the effectiveness of symptom management.
Q: What is the benefit of a long-acting injection like Xeplion?
A: The long-acting design is intended to achieve and maintain continuous therapeutic action for a longer duration, supporting treatment consistency without the need for daily oral dosing. The structured initiation phase is intended to rapidly attain plasma concentrations that support therapeutic action.
Q: Do I need to stop taking my oral medication when starting Xeplion?
A: The manufacturer's advice is that previous oral antipsychotics can be gradually discontinued at the time of initiation of treatment with the Xeplion injection. This transition process is always managed by a healthcare provider.
Q: How quickly does Xeplion start to work after the first injection?
A: The recommended initiation schedule, which involves two injections one week apart, is specifically designed to rapidly attain therapeutic concentrations of the active medicine. However, official regulatory documents do not specify an exact timeframe for when a patient should expect to experience the onset of symptom management effects.
Q: Is it normal to feel tired or drowsy after the Xeplion injection?
A: Feeling tired (sedation) or dizzy (dizziness) are common adverse reactions documented in official product information. Sedation is listed as a common effect that may be dose-related. If this feeling is severe or persistent, it should be discussed with a healthcare professional.
Q: Can Xeplion affect my ability to drive or operate machinery?
A: Official product information advises caution regarding driving or operating machinery. This is because the medicine may cause adverse effects like dizziness, extreme tiredness, and vision problems that may affect alertness required to perform skilled tasks.
Q: Is Xeplion used for any conditions other than schizophrenia?
A: Yes, in addition to schizophrenia, the medicine is also officially approved and indicated for the treatment of schizoaffective disorder.
Q: Does Xeplion cause tremors or muscle stiffness?
A: Yes, Parkinsonism is listed as a common adverse reaction in official product information. This term refers to a group of movement-related effects that can include symptoms such as tremor and muscle stiffness, along with other movement disorders like Akathisia.
Q: Can Xeplion affect blood sugar levels?
A: Official regulatory documents specify that hyperglycaemia (high blood sugar) and the worsening of pre-existing diabetes have been observed. Official documents describe that regular monitoring for signs of high blood sugar or diabetes is an element of care.
Q: Is it safe to drink alcohol while I am being treated with Xeplion?
A: Alcohol should be avoided when combined with the medicine. This is due to the potential for additive Central Nervous System (CNS) depression (increased sleepiness or slowed reflexes) when used together, as noted in the official interactions information.
Q: Are there any long-term effects of taking Xeplion?
A: Studies examining the medicine have been conducted for periods up to 52 weeks (one year). Long-term monitoring focuses on the potential for metabolic changes (such as weight gain and blood sugar changes) and the possible development of late-appearing movement disorders like Tardive Dyskinesia.
Q: Can I take herbal supplements while on Xeplion?
A: The co-administration of strong CYP3A4 and P-glycoprotein (P-gp) inducers, such as the herbal product St John’s Wort, must be avoided. These substances can decrease the amount of the drug in the blood, potentially making it less effective.
Q: Does Xeplion affect sleep patterns?
A: Insomnia (difficulty sleeping) is listed as a very common adverse reaction, occurring in at least 1 in 10 patients. Conversely, sedation (sleepiness) is listed as a common effect. Any changes to sleep patterns should be discussed with a healthcare provider.
Q: Are there specific lab tests required while on Xeplion?
A: Official documents recommend routine monitoring related to specific potential side effects. This includes the monitoring of body weight, as well as checks for signs of high blood sugar (especially in those with diabetes), and blood tests to monitor white blood cell levels.
Q: What is the risk of an allergic reaction to Xeplion?
A: The medicine is contraindicated (must not be used) in patients with a known hypersensitivity (allergic reaction) to paliperidone or the related medicine, risperidone. Severe allergic reactions (such as anaphylaxis) are also noted as rare events in regulatory documents.
Q: Is Xeplion treatment usually for a short time or long-term?
A: The medicine is officially approved and indicated for the maintenance treatment of symptoms. This implies that it is intended for sustained, long-term pharmacological support rather than a short-term course.
Q: Does Xeplion make it harder to think or concentrate?
A: Official product information advises caution when performing activities that require alertness because of the potential for the medicine to cause dizziness and extreme tiredness, which can impair one's cognitive function and concentration.
Q: Can Xeplion cause problems with vision or eyes?
A: Official prescribing information advises caution due to possible vision problems. Furthermore, reports exist of a condition called Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery in patients treated with this class of medicine, which is a condition that should be addressed with the surgeon.
Q: Is it common for people to switch from oral paliperidone to Xeplion?
A: Yes, official regulatory documents include specific, structured instructions for switching patients who have been previously stabilized on oral paliperidone (Invega) to the Xeplion injection as part of their long-term treatment plan.
